# Dor/isl PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dor-isl

> The next catalyst for dor/isl, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Sep to Dec 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | dor/isl |
| Codes | MK-8591A |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [HIV-1 Infection](https://sec-api.dev/indications/hiv-1-infection), HIV Infection, HIV-1 |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: HIV-1 Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05705349 (DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05705349

### October 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05766501 (A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05766501

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HIV-1; HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07862569 (DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07862569

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: HIV-1; HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07862569 (DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07862569

## Same indication

- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir) (GILD)
- [MK-8591A](https://sec-api.dev/pdufa/mk-8591a) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dor-isl.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dor/isl PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dor-isl

```bibtex
@misc{secapidev_pdufa_dor_isl_20261116,
  title        = {Dor/isl PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dor-isl}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dor_isl_20261116","title":"Dor/isl PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dor-isl","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
